Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Witt, A E
Lee, T I
Azzam, D J
Cohick, E B
Gropper, A B
Richardson, A L
Young, R A
Ince, T ANote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationWitt, A. E., C. Lee, T. I. Lee, D. J. Azzam, B. Wang, C. Caslini, F. Petrocca, et al. 2017. “Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.” Oncogene 36 (12): 1707-1720. doi:10.1038/onc.2016.337. http://dx.doi.org/10.1038/onc.2016.337.
AbstractTumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are resistant to conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest in CSCs, it has been difficult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present evidence that specific histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumour-cells (nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into CSC-specific therapies.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32630581
- HMS Scholarly Articles